Viyash Scientific Ltd Downgraded to Sell Amid Mixed Fundamentals and Bearish Technicals

Quality Assessment: Weak Long-Term Fundamentals Despite Recent Strength

While Viyash Scientific has demonstrated outstanding financial performance in the third quarter of FY25-26, the company’s long-term fundamental strength remains underwhelming. The average Return on Capital Employed (ROCE) over recent years stands at a modest 7.40%, signalling limited efficiency in generating returns from its capital base. This contrasts sharply with the half-year ROCE peak of 18.65%, reflecting recent operational improvements but insufficient to offset historical weaknesses.

Net sales have grown at an annualised rate of 14.17% over the past five years, with operating profit increasing at 12.25% annually. These growth rates, while positive, are considered moderate within the pharmaceuticals industry, where innovation and rapid expansion often drive higher metrics. Furthermore, the company’s ability to service debt is a concern, with a high Debt to EBITDA ratio of 7.93 times, indicating significant leverage and potential financial risk.

On the positive side, Viyash Scientific has declared positive results for eight consecutive quarters, with operating profit growth of 78.2% in the latest quarter and an operating profit to interest coverage ratio of 10.49 times, highlighting improved operational cash flow and interest servicing capacity in the short term. Additionally, the debt-equity ratio remains relatively low at 0.61 times for the half-year period, suggesting a manageable capital structure despite the high Debt to EBITDA ratio.

Valuation: Expensive Yet Discounted Relative to Peers

Viyash Scientific’s valuation presents a nuanced picture. The company’s ROCE of 18.1% in the half-year period has contributed to an elevated Enterprise Value to Capital Employed (EV/CE) ratio of 6.8, indicating a relatively expensive valuation on a capital efficiency basis. However, the stock is trading at a discount compared to its peers’ average historical valuations, suggesting some market scepticism or undervaluation relative to sector benchmarks.

Over the past year, the stock has delivered a robust return of 25.77%, outperforming the Sensex which declined by 5.47% over the same period. This outperformance is supported by a remarkable 138.8% increase in profits, resulting in a Price/Earnings to Growth (PEG) ratio of 1.5. While this PEG ratio is not excessively high, it indicates that the stock’s price growth is somewhat aligned with its earnings growth, leaving limited margin for valuation expansion.

Financial Trend: Mixed Signals Amid Strong Quarterly Results

Despite the downgrade, Viyash Scientific’s recent financial trends have been encouraging. The company reported outstanding results in December 2025, with operating profit growth of 78.2% and the highest operating profit to interest coverage ratio recorded at 10.49 times. Promoter confidence has also surged, with a 9.1% increase in promoter stake over the previous quarter, now holding 61.43% of the company’s equity. This stake increase signals strong insider belief in the company’s future prospects.

However, the long-term financial trajectory remains less favourable. The company’s net sales and operating profit growth rates over five years, while positive, are modest compared to industry leaders. Additionally, the high Debt to EBITDA ratio of 7.93 times raises concerns about the company’s ability to sustain growth without increasing financial risk. These mixed financial signals contribute to a cautious outlook despite recent operational successes.

Technical Analysis: Shift from Mildly Bullish to Mildly Bearish

The most significant trigger for the downgrade is the deterioration in technical indicators. Viyash Scientific’s technical grade has shifted from mildly bullish to mildly bearish, reflecting weakening momentum and increased selling pressure. Key weekly technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory have turned bearish, while monthly indicators remain mixed with some mildly bullish signals.

Specifically, the weekly MACD and Bollinger Bands are bearish, signalling downward momentum in the short term. The KST indicator and Dow Theory on both weekly and monthly timeframes also suggest mild bearishness. Conversely, the monthly MACD remains bullish, and the On-Balance Volume (OBV) shows a mildly bullish trend, indicating some underlying accumulation. The daily moving averages are mildly bullish, but this has not been sufficient to offset the broader negative technical sentiment.

Price action supports this technical caution. The stock closed at ₹181.30 on 23 March 2026, down 3.79% from the previous close of ₹188.45. It has declined 7.03% over the past week and 17.40% over the past month, underperforming the Sensex’s respective declines of 3.72% and 12.72%. The 52-week high stands at ₹260.30, while the low is ₹111.00, indicating a wide trading range but recent weakness near the lower end.

Comparative Returns and Market Context

Over longer horizons, Viyash Scientific has delivered mixed returns relative to the broader market. The stock has outperformed the Sensex over the last one year (25.77% vs. -5.47%) and three years (146.16% vs. 25.50%), demonstrating strong medium-term growth. However, over five and ten years, the stock has lagged significantly, with returns of -25.16% and 10.28% respectively, compared to the Sensex’s 45.24% and 186.91% gains. This uneven performance history underscores the company’s volatile growth trajectory and reinforces the cautious stance.

Conclusion: Downgrade Reflects Technical Weakness and Valuation Risks Despite Operational Strength

The downgrade of Viyash Scientific Ltd from Hold to Sell by MarketsMOJO on 23 March 2026 is primarily driven by a shift in technical indicators from mildly bullish to mildly bearish, signalling weakening market momentum. While the company has delivered outstanding quarterly results and demonstrated strong promoter confidence, its long-term fundamental metrics remain weak, with modest growth rates and high leverage concerns.

Valuation remains expensive on capital employed metrics, though the stock trades at a discount relative to peers. The mixed financial trends, combined with recent price underperformance and deteriorating technical signals, justify a cautious stance. Investors should weigh the company’s recent operational improvements against its longer-term risks and consider alternative opportunities within the Pharmaceuticals & Biotechnology sector.

Given these factors, the Sell rating reflects a prudent approach to managing risk amid uncertain technical and fundamental outlooks for Viyash Scientific Ltd.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today